Benzinga | Nov 2, 2021 10:57AM EDT

Evolus Initiates Phase II Program With "Extra Strength" Dose For Extended Duration

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has initiated a clinical program to study an "extra strength" dose for extended duration of Jeuveau(r) (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and first and only neurotoxin dedicated exclusively to aesthetics.

"With this program, Evolus is pursuing a neurotoxin development strategy with an 'extra strength' dose that complements our 'original strength' Jeuveau(r). We believe Evolus is the only company that can capitalize on this opportunity given the combination of our aesthetics-only business model, together with the precision of the Jeuveau(r) product," said David Moatazedi, President and Chief Executive Officer. "This strategy would provide an expanded product offering for consumers who may desire a different performance profile with a longer duration."

"Our original Jeuveau(r) clinical program rapidly achieved approval in the U.S., Canada and 31 European countries in five years. Our proven clinical development team has initiated Phase II study preparation, and we look forward to enrolling our first patient in the first quarter of 2022 with final results expected in the first half of 2023," said Rui Avelar, M.D., Chief Medical Officer and Head of Research and Development. "One of the primary safety considerations of neurotoxins is related to their spread, and we believe that the precise nature of Jeuveau(r) is well suited for a trial exploring a higher dose."